Extending endocrine therapy with aromatase inhibitors among women ages 50–79 had a small absolute reduction in the lifetime probability of breast cancer death (0.16%), with a reduction of 0.10 at 15 years (Figure 1, Panel B, and Table 2). This evidence concerns the gene CYP19A1 and breast carcinoma.